{"id":15878,"date":"2020-06-04T15:39:50","date_gmt":"2020-06-04T15:39:50","guid":{"rendered":"https:\/\/sbpt.org.br\/portal\/?p=15878"},"modified":"2020-06-04T18:48:54","modified_gmt":"2020-06-04T18:48:54","slug":"resumo-cientifico-covid-15","status":"publish","type":"post","link":"https:\/\/sbpt.org.br\/portal\/resumo-cientifico-covid-15\/","title":{"rendered":"COVID-19: resumos de artigos selecionados – parte 15"},"content":{"rendered":"
4 de junho de 2020.<\/em><\/p>\n Confira a resenha do artigo sobre coagulopatia em COVID-19, publicado na Blood, e do conte\u00fado sobre diabetes e COVID-19, disponibilizado na revista Nature. Conte\u00fado oferecido com o apoio da GSK:\u00a0<\/p>\n COVID-19 AND ITS IMPLICATIONS FOR THROMBOSIS AND ANTICOAGULATION<\/strong><\/p>\n\n\n Autores:<\/strong><\/p>\n\n\n\n Connors JM1<\/sup>, Levy JH2<\/sup><\/p>\n\n\n\n Proced\u00eancia:<\/strong><\/p>\n\n\n\n 1<\/sup>Escola de Medicina de Harvard, Estados Unidos; <\/p>\n\n\n\n 2<\/sup>Universidade Duke Escola de Medicina, Estados\nUnidos.<\/p>\n\n\n\n Resumo<\/strong><\/p>\n\n\n\n No presente artigo, os autores revisam dados oriundos\nprincipalmente da prov\u00edncia de Wuhan, na China, referentes \u00e0s anormalidades da\ncoagula\u00e7\u00e3o que ocorrem em associa\u00e7\u00e3o com a COVID-19 (coronavirus disease 2019)<\/em> e tecem sugest\u00f5es para o manejo de\nquest\u00f5es cl\u00ednicas que tendem a surgir em decorr\u00eancia destas anormalidades. Os\nautores tamb\u00e9m analisam dados publicados que relacionam inflama\u00e7\u00e3o com altera\u00e7\u00f5es\nda coagula\u00e7\u00e3o, acometimento endotelial associado \u00e0 COVID-19 e dados atualmente\ndispon\u00edveis para orientar quest\u00f5es relativas ao manejo da coagula\u00e7\u00e3o no\ncontexto da doen\u00e7a.<\/p>\n\n\n\n As principais assertivas relatadas no artigo\ns\u00e3o:<\/p>\n\n\n\n Os\nautores concluem que um esfor\u00e7o a n\u00edvel global deve ser realizado para que,\n\u00e0 medida que o conhecimento sobre a\nfisiopatologia da COVID-19 evolui, mudan\u00e7as no manejo pr\u00e1tico dos pacientes\ntamb\u00e9m ocorram. <\/p>\n\n\n\n Refer\u00eancia:<\/p>\n\n\n\n CONNORS, JM. Et al. Covid-19 and Its\nImplications for Thrombosis and Anticoagulation. Blood.\n2020 Apr 27. doi:10.1182\/blood.2020006000<\/p>\n\n\n\n Clique aqui para ler o artigo na \u00edntegra.<\/a><\/p>\n\n\n\n DIABETES AND\nCOVID-19: EVIDENCE, CURRENT STATUS AND UNANSWERED RESEARCH QUESTIONS<\/strong><\/p>\n\n\n\n Autores:<\/p>\n\n\n\n Gupta R.1<\/sup>,\nHussain A2,3<\/sup>., Misra A1,3<\/sup>.<\/p>\n\n\n\n Proced\u00eancia:<\/p>\n\n\n\n 1<\/sup>Fortis CDOC Hospital, Chirag Enclave, New\nDelhi, India<\/p>\n\n\n\n 2<\/sup>Chronic Disease\u2014Diabetes, NORD University,\nStj\u00f8rdal, Norway) and (Medicine, Federal University of Ceara (UFC), Ceara,\nBrazil<\/p>\n\n\n\n 3<\/sup>National Diabetes, Obesity and Cholesterol\nFoundation, New Delhi, India) and (Diabetes Foundation (India), New Delhi,\nIndia)<\/p>\n\n\n\n Resumo<\/strong><\/p>\n\n\n\n Este artigo\nde revis\u00e3o aborda recentes evid\u00eancias e quest\u00f5es que permanecem controversas em\nrela\u00e7\u00e3o a pacientes com diabetes mellitus que adquiriram a COVID-19 (coronavirus disease 2019)<\/em>. <\/p>\n\n\n\n Seguem as principais considera\u00e7\u00f5es:<\/p>\n\n\n\n Refer\u00eancias bibliogr\u00e1ficas:<\/p>\n\n\n\n 1. Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ,\nCook DG. Glycemic control and risk of infections among people\nwith type 1 or type 2 diabetes in a large primary care cohort study. Diabetes\nCare 2018;41:513\u201321.<\/p>\n\n\n\n 2. Ferlita S,\nYegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 diabetes mellitus\nand altered immune system leading to susceptibility to pathogens, especially\nmycobacterium tuberculosis. J Clin Med. 2019;8:2219.<\/p>\n\n\n\n 3. Nyambuya\nTM, Dludla PV, Mxinwa V, Nkambule BB. T-cell activation and cardiovascular risk\nin adults with type 2 diabetes mellitus: A systematic review and meta-analysis.\nClin Immunol. 2020;210:108313.<\/p>\n\n\n\n 4. Maddaloni\nE, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two\npandemics. Diabetes Metab Res Rev. 2020:e33213321.<\/p>\n\n\n\n 5. Huttunen R, Syrj\u00e4nen J.\nObesity and the risk and outcome of infection. Int J Obes. 2013;37:333\u201340.<\/p>\n\n\n\n 6. Ji HL,\nZhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a common risk factor\nfor COVID-19 susceptibility. Physiol Rev. 2020;100:1065\u201375.<\/p>\n\n\n\n Refer\u00eancia:<\/p>\n\n\n\n Gupta\nR, et al. Diabetes and Covid-19: Evidence, Current Status and Unanswered\nResearch Questions. Eur J Clin Nutr. 2020 May 13.\ndoi.10.1038\/s41430-020-0652-<\/p>\n\n\n\n Clique aqui para ler o artigo na \u00edntegra.<\/a><\/p>\n\n\n Apoio:<\/p>\n